v3.26.1
Note 11 - Stock-Based Compensation (Tables)
3 Months Ended
Mar. 31, 2026
Notes Tables  
Share-Based Payment Arrangement, Option, Activity [Table Text Block]

 

 

 

 

 

 

Weighted

 

 

Remaining

 

 

 

 

 

 

 

Number of

 

 

Average

 

 

Contractual

 

 

Intrinsic

 

 

 

Stock Options

 

 

Exercise Price

 

 

Term (Years)

 

 

Value(2)

 

Outstanding stock options at December 31, 2025

 

 

10,272,642

 

 

$

1.62

 

 

 

7.5

 

 

$

396

 

Granted(1)

 

 

2,228,500

 

 

$

1.35

 

 

 

 

 

 

 

 

 

Exercised

 

 

(15,157

)

 

$

1.29

 

 

 

 

 

 

 

 

 

Forfeited

 

 

(132,443

)

 

$

1.33

 

 

 

 

 

 

 

 

 

Outstanding stock options at March 31, 2026(3)

 

 

12,353,542

 

 

$

1.57

 

 

 

7.6

 

 

$

472

 

Vested and exercisable stock options at March 31, 2026

 

 

7,680,579

 

 

$

1.74

 

 

 

6.6

 

 

$

402

 

Share-Based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]

 

 

 

 

 

Weighted

 

 

 

Number of

 

 

Average

 

 

 

Restricted

 

 

Grant Date

 

 

 

Stock Awards

 

 

Fair Value

 

Unvested restricted stock awards as of December 31, 2025

 

 

6,584,240

 

 

$

4.02

 

Granted

 

 

5,746,000

 

 

 

1.36

 

Vested

 

 

(20,622

)

 

 

1.49

 

Forfeited

 

 

(14,378

)

 

 

1.49

 

Unvested restricted stock awards as of March 31, 2026

 

 

12,295,240

 

 

$

2.78

 

Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]

 

 

Three Months Ended

 

 

 

March 31,

 

 

 

2026

 

 

2025

 

Lucid Diagnostics 2018 Equity Plan – cost of revenue

 

$

113

 

 

$

33

 

Lucid Diagnostics 2018 Equity Plan – sales and marketing

 

 

253

 

 

 

221

 

Lucid Diagnostics 2018 Equity Plan - general and administrative

 

 

905

 

 

 

600

 

Lucid Diagnostics 2018 Equity Plan - research and development

 

 

131

 

 

 

95

 

PAVmed 2014 Equity Plan - cost of revenue

 

 

1

 

 

 

38

 

PAVmed 2014 Equity Plan - sales and marketing

 

 

2

 

 

 

18

 

PAVmed 2014 Equity Plan - general and administrative

 

 

2

 

 

 

1

 

PAVmed 2014 Equity Plan - research and development

 

 

4

 

 

 

24

 

Total stock-based compensation expense

 

$

1,411

 

 

$

1,030

 

Schedule of Unrecognized Compensation Expense by Plan [Table Text Block]

 

 

 

 

 

Weighted

 

 

 

 

 

 

Average

 

 

 

 

 

 

Remaining

 

 

 

Unrecognized

 

 

Service Period

 

 

 

Expense

 

 

(Years)

 

Lucid Diagnostics 2018 Equity Plan

 

 

 

 

 

 

Stock Options

 

$

3,696

 

 

 

2.1

 

Restricted Stock Awards

 

$

10,415

 

 

 

2.3

 

PAVmed 2014 Equity Plan

 

 

 

 

 

 

Stock Options

 

$

30

 

 

 

1.2

 

Restricted Stock Awards

 

$

108

 

 

 

2.1

 

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

 

 

Three Months Ended March 31,

 

 

 

2026

 

 

2025

 

Expected term of stock options (in years)

 

 

5.8

 

 

 

5.8

 

Expected stock price volatility

 

 

67

%

 

 

68

%

Risk free interest rate

 

 

3.8

%

 

 

4.4

%

Expected dividend yield

 

 

%

 

 

%